Approximately 300 patients will be entered into this study taking place throughout the United States, Canada and the United Kingdom. This study aims to determine if an investigational drug is safe and effective for treating the symptoms of C. difficile-associated diarrhea and lowering the risk of repeat episodes of diarrhea. The investigational drug will be evaluated in comparison to current standard antibiotic treatment, so all patients will receive active medication. All study-related care is provided including doctor visits, physical exams, laboratory tests and study medication. Total length of participation is approximately 10 weeks.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Enrollment
300
Unnamed facility
Mobile, Alabama, United States
Unnamed facility
Phoenix, Arizona, United States
Unnamed facility
Tucson, Arizona, United States
Unnamed facility
Little Rock, Arkansas, United States
Unnamed facility
Sacramento, California, United States
Unnamed facility
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Newark, Delaware, United States
Unnamed facility
Bay Pines, Florida, United States
Unnamed facility
Brandon, Florida, United States
Unnamed facility
Hollywood, Florida, United States
Unnamed facility
Naples, Florida, United States
...and 89 more locations